But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Patients with certain chronic eye diseases, like glaucoma and macular degeneration, typically either use inefficient eyedrops or have to get injections directly into their eyes. A team of ...

Oct 25 (Reuters) - Bausch Health Companies Inc and Clearside Biomedical Inc said on Monday they received approval from the U.S. health regulator for their eye injection, giving patients access to ...